After two and a half years providing COVID-19 testing services to New England and beyond – including over 1.6 million tests – JAX’s Clinical Genomics Laboratory has suspended COVID-19 testing as of Friday, July 29, 2022, in alignment with the significant decrease in COVID-19 PCR testing demand. We will continue to monitor the pandemic and testing needs, and are prepared to reinstate testing services should demand increase. We are grateful to our community partners for supporting and collaborating with the JAX CLIA lab on this important endeavor.
While testing and sequencing services are no longer JAX’s focus at present, we are continuing our vital COVID-19 research, including the investigating the biological complexities of COVID, long COVID, and developing mouse models for the study of this virus.
The JAX CLIA lab’s focus has now returned to serving the oncology community with complex tumor profiling assays that help cancer patients and their physicians learn about specific tumors and provide insight into the most promising treatment options. We are proud of the continued role we play in improving human health and empowering the global biomedical community in our shared quest to improve human health.
The Hartford Business Journal has recognized JAX among its 2020 Health Care Heroes in the Innovation category, recognizing an organization that has made a positive advancement in medical care or medical science.
JAX researchers have created a panel of genetically diverse mice that accurately model the highly variable human response to SARS-CoV-2 infection. This will allow scientists to model patient variation in COVID-19 outcome.
Chia-Lin Wei looked at SARS-CoV-2 RNA genomes and sub-genomic viral RNA in symptomatic and asymptomatic patients and found distinct, consistent differences between the patient groups. The findings have important implications for developing better COVID-19 risk mitigation and clinical strategies.